Results 191 to 200 of about 37,178 (276)

Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti‐inflammatory drug, and its lack of clinically significant CYP inhibition potential

, 2002
Shigeru Furuta, Nobuyoshi Akagawa, Emiko Kamada, Akio Hiyama, Yoshihiro Kawabata, Nobuhiko Kowata, Atsuhiro Inaba, Anne Matthews, Michael Hall, Tadashi Kurimoto   +9 more
openalex   +2 more sources

PP148—Influence of CYP2C9 IVS8-109A>T Polymorphism on Losartan Oxidation in Healthy Ecuadorians [PDF]

, 2013
Pedro Dorado, Alicia Gallego, Leonardo J Beltrán, Eva Peñas‐Lledó, Enrique Terán, Adrián LLerena   +5 more
openalex   +1 more source

Association Between <i>CYP2C9</i> and <i>CYP2C19</i> Genetic Polymorphisms and Antiseizure Medication-Induced Adverse Reactions Among Peruvian Patients with Epilepsy. [PDF]

Pharmaceuticals (Basel)
Alvarado AT, Ignacio-Cconchoy FL, Espinoza-Retuerto JC, Contreras-Macazana RM, Quiñones LA, García JA, Bendezú MR, Chávez H, Surco-Laos F, Laos-Anchante D, Cuba-Garcia PA, Melgar-Merino EJ, Pari-Olarte B, Bonifaz-Hernández M, Almeida-Galindo JS, Kong-Chirinos J, Pariona-Llanos R, Aguilar-Ramírez P, Varela NM.   +18 more
europepmc   +1 more source

Identification of diagnostic and prognostic biomarkers in lung adenocarcinoma through integrated bioinformatics analysis and real time PCR validation. [PDF]

Sci Rep
Hossein Zadeh R, Hossein Zadeh R, Hajimoradi M, Islampanah M, Zarimeidani F, Rahmati R, Ahmadinia M, Bahrami N, Mohamadnia A, Shafaghi S, Nazari E.   +10 more
europepmc   +1 more source

Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent [PDF]

, 2014
Acimovic J, Bernhardt R, Kocjan D, Kuzman D, Kóbori László, Kőhalmy Krisztina, Monostory Katalin, Pascussi JM, Rozman D, Szabó Pál Tamás, Temesvári Manna, Wilzewski B   +11 more
core   +1 more source

Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers. [PDF]

Clin Transl Sci
Etkins J, So GC, Lu JBL, Koyama S, Gisch DL, Melo Ferreira R, Cheng YH, McClara K, Jun J, Miller M, Desta Z, Eadon MT.   +11 more
europepmc   +1 more source

Genetisch bedingte Unterschiede der CYP2C9-Aktivität: Einfluss von Enzyminduktion

, 2007
Jonas Kuon
openalex   +2 more sources

Clinical Evaluation of Drug-Drug Interactions With Aficamten. [PDF]

Clin Transl Sci
Maharao N, Xu D, Divanji P, Simkins TJ, Li J, Dumitrescu C, Solanki P, Griffith A, Heitner SB, Kupfer S, German P, Lutz JD.   +11 more
europepmc   +1 more source

Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response

, 2013
José Antonio Nastasi-Catanese, Jorge Ramón Padilla‐Gutiérrez, Yeminia Valle, F. Ortega-Gutiérrez, Martha Patricia Gallegos‐Arreola, Luis E. Figuera   +5 more
openalex   +1 more source

Pharmacogenetic Associations with Statin Regimen Modification, Intolerance, and Adverse Outcomes in Coronary Artery Disease Patients. [PDF]

Pharmaceuticals (Basel)
Abdel-Latif R, Mohammed S, Saad M, Kunji K, Al-Muftah W, El-Menyar A, Al Suwaidi J.   +6 more
europepmc   +1 more source